Results 61 to 70 of about 9,493 (159)

The Complement System in Post‐Transplant Kidney Injury

Organ Medicine, EarlyView.
Mengsi Hu
wiley   +1 more source

Comparing Efficacy and Safety of Various Monoclonal Antibodies in Myasthenia Gravis: A Systematic Review and Network Meta‐Analysis of Randomized Controlled Trials

Brain and Behavior, Volume 16, Issue 6, June 2026.
ROZ 10 mg/kg ranked best for reducing MG‐ADL. BAT 680 mg significantly reduced QMG and ranked best. BAT 340 mg had the highest probability of reducing the MGC score. ECU significantly decreased MG‐QoL 15r and ranked best. BEL 10 mg/kg had the highest likelihood of reducing adverse events.
Muhammad Hassan Waseem, Zain ul Abideen, Minahil Iqbal, Saniya Ishtiaq, Pawan Kumar Thada, Adam A. Dmytriw   +5 more
wiley   +1 more source

Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti‐C5 therapy

HemaSphere, Volume 10, Issue 6, June 2026.
Abstract Patients with paroxysmal nocturnal hemoglobinuria (PNH) on anti‐C5 often experience extravascular hemolysis with anemia. Iptacopan, the first oral proximal complement inhibitor targeting factor B, has shown efficacy and safety in PNH patients. APPULSE‐PNH (NCT05630001), a phase 3b, single‑arm, open‐label trial, enrolled adult patients with PNH
Austin Kulasekararaj, Flore S. de Fontbrune, Anna Gaya, Ilene Weitz, David J. Kuter, Bhumika J. Patel, David J. Araten, Abhay Singh, Jun H. Jang, Richard J. Kelly, Eros Di Bona, Michael Loschi, Vinod Pullarkat, Jörg Schubert, Rosario Notaro, Mustafa N. Yenerel, Joan Beckman, Nicolas Blin, Irina Murakhovskaya, Jens Panse, Eloy Roman, Alexander Röth, Hubert Schrezenmeier, Srinivas Tantravahi, Régis P. de Latour, Navin Mahajan, Luca Monaco, Tao Ding, Tomasz Lawniczek, Philippe Ferber, Marion Dahlke, Antonio M. Risitano   +31 more
wiley   +1 more source

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.

PLoS ONE, 2020
BackgroundEculizumab has transformed management of paroxysmal nocturnal hemoglobinuria (PNH) since its approval. However, its biweekly dosing regimen remains a high treatment burden.
John Devin Peipert, Austin G Kulasekararaj, Anna Gaya, Saskia M C Langemeijer, Susan Yount, F Ataulfo Gonzalez-Fernandez, Emilio Ojeda Gutierrez, Christa Martens, Amy Sparling, Kimberly A Webster, David Cella, Ioannis Tomazos, Masayo Ogawa, Caroline I Piatek, Richard Wells, Flore Sicre de Fontbrune, Alexander Röth, Lindsay Mitchell, Anita Hill, Karen Kaiser   +19 more
doaj   +1 more source

Eculizumab [PDF]

British Journal of Clinical Pharmacology, 2009
Eline A, Dubois, Adam F, Cohen
openaire   +2 more sources

RASGRP1 Deficiency Manifesting as Severe Vasculopathy and Fatal Autoimmune Hemolytic Anemia

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Background RASGRP1 deficiency is a rare inborn error of immunity characterized by immunodeficiency, autoimmunity, and lymphoproliferation. Results We report a 5‐year‐old male with novel homozygous splice‐donor mutations in RASGRP1(c.1720+1G>A and c.1720+2T>C) who presented with severe vasculopathy (ischemic stroke and thrombosis), secondary ...
Kosar Asna Ashari, Bahareh Yaghmaie, Neda Pak, Mohammad Shahrooei, Vahid Ziaee, Nima Parvaneh   +5 more
wiley   +1 more source

Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis

Leukemia Research Reports, 2015
Pregnancy in women with paroxysmal nocturnal hemoglobinuria (PNH) is associated with increased maternal and fetal morbidity and mortality. There is limited published experience regarding therapy of PNH during pregnancy.
Ruby Sharma, Alla Keyzner, Johnson Liu, Thomas Bradley, Steven L. Allen   +4 more
doaj   +1 more source

Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring

Annals of Clinical and Translational Neurology, Volume 13, Issue 6, Page 1301-1302, June 2026.
Francesco Saccà, Ryan Pelto
wiley   +1 more source

Experience Using Efgartigimod to Treat Juvenile Myasthenia Gravis in China: A Multicenter Retrospective Study

Muscle &Nerve, Volume 73, Issue 6, Page 1025-1031, June 2026.
ABSTRACT Introduction/Aims Current therapeutic management of juvenile myasthenia gravis (JMG) predominantly relies on conventional immunosuppressive therapies and expert consensus extrapolated from adult data, creating a critical gap in high‐quality, pediatric‐specific clinical evidence.
Jing Lin, Guoyan Qi, Susan Luo, Qilong Jiang, Bitao Bu, Min Liu, Yuzhen Wei, Meigui Han, Junhong Yang, Zhilan Zhao, Lili Zhang, Yifan Zhang, Haoyou Xu, Xingjie Hao, Zhijun Li   +14 more
wiley   +1 more source

Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis

Therapeutic Advances in Neurological Disorders, 2020
Background: Eculizumab is a humanized monoclonal antibody that targets complement protein C5 and inhibits terminal complement-mediated damage at the neuromuscular junction.
Munenori Oyama, Kensuke Okada, Masayuki Masuda, Yuko Shimizu, Kazumasa Yokoyama, Akiyuki Uzawa, Naoki Kawaguchi, Ryotaro Ikeguchi, Yasunobu Hoshino, Taku Hatano, Yukiko Ozawa, Jin Nakahara, Hitoshi Aizawa, Kazuo Kitagawa, Nobutaka Hattori, Satoshi Kuwabara, Hiroyuki Murai, Shigeaki Suzuki   +17 more
doaj   +1 more source